{"log_id": 2736624518444583134, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 2e-06, "average": 0.998341, "min": 0.995293}, "location": {"width": 127, "top": 222, "height": 28, "left": 215}, "words": "【儿童用药】"}, {"probability": {"variance": 3e-06, "average": 0.999252, "min": 0.989893}, "location": {"width": 742, "top": 278, "height": 35, "left": 254}, "words": "由于缺乏此亚组人群的安全与有效性数据,因此不建议儿童与青少年使用本"}, {"probability": {"variance": 0, "average": 0.999528, "min": 0.999528}, "location": {"width": 24, "top": 322, "height": 25, "left": 209}, "words": "品"}, {"probability": {"variance": 3e-06, "average": 0.998548, "min": 0.995288}, "location": {"width": 127, "top": 379, "height": 28, "left": 215}, "words": "【老年用药】"}, {"probability": {"variance": 0.001974, "average": 0.982587, "min": 0.786798}, "location": {"width": 748, "top": 435, "height": 35, "left": 242}, "words": "在临床试验中,大约82%(1146/1406)的随机接受本品治疗的患者年龄≥65"}, {"probability": {"variance": 0.014705, "average": 0.957658, "min": 0.394051}, "location": {"width": 776, "top": 469, "height": 36, "left": 206}, "words": "岁,大约55%(771406)的患者年龄≥75岁。在这些试验中,随着年龄增加"}, {"probability": {"variance": 1.3e-05, "average": 0.998173, "min": 0.985929}, "location": {"width": 786, "top": 503, "height": 36, "left": 209}, "words": "本品的有效性或安全性未出现显著差异。在人群药代动力学分析中,经过肌酐清"}, {"probability": {"variance": 0, "average": 0.999445, "min": 0.997872}, "location": {"width": 525, "top": 540, "height": 33, "left": 206}, "words": "除率校正后,年龄对于全身暴露水平不存在显著影响"}, {"probability": {"variance": 5e-06, "average": 0.997897, "min": 0.993696}, "location": {"width": 171, "top": 603, "height": 30, "left": 215}, "words": "【药物相互作用】"}, {"probability": {"variance": 7e-06, "average": 0.998624, "min": 0.988479}, "location": {"width": 389, "top": 664, "height": 29, "left": 254}, "words": "目前尚未进行正式的药物相互作用研究"}, {"probability": {"variance": 3e-06, "average": 0.997932, "min": 0.995182}, "location": {"width": 124, "top": 725, "height": 28, "left": 215}, "words": "【药物过量】"}, {"probability": {"variance": 0.004396, "average": 0.986661, "min": 0.612346}, "location": {"width": 743, "top": 783, "height": 34, "left": 254}, "words": "临床试验与上市后数据中己报告了意外用药过量的病例。与这些报告的病例"}, {"probability": {"variance": 8e-06, "average": 0.998748, "min": 0.985422}, "location": {"width": 787, "top": 818, "height": 34, "left": 207}, "words": "最常相关的不良事件有眼内压升高和眼痛。如果出现药物过量,应监测眼内压并"}, {"probability": {"variance": 6.6e-05, "average": 0.99679, "min": 0.966048}, "location": {"width": 358, "top": 856, "height": 28, "left": 207}, "words": "治疗(如果主治医生认为有必要时)"}, {"probability": {"variance": 0.000139, "average": 0.988372, "min": 0.9647}, "location": {"width": 124, "top": 918, "height": 28, "left": 215}, "words": "【临床试验】"}, {"probability": {"variance": 4e-06, "average": 0.99852, "min": 0.99358}, "location": {"width": 164, "top": 978, "height": 27, "left": 206}, "words": "药效动力学性质"}, {"probability": {"variance": 8e-06, "average": 0.997971, "min": 0.990065}, "location": {"width": 741, "top": 1033, "height": 36, "left": 253}, "words": "本品是一种人源化的重组单克隆抗体片段(Fab),靶向抑制人血管内皮生长"}, {"probability": {"variance": 0.001536, "average": 0.982749, "min": 0.777344}, "location": {"width": 786, "top": 1070, "height": 31, "left": 208}, "words": "因子A(VEGF-A)。它与VEGF-A亚型(即VEGF10、VEGF121和VEGF165)以较"}, {"probability": {"variance": 0.004929, "average": 0.973649, "min": 0.624438}, "location": {"width": 790, "top": 1102, "height": 34, "left": 207}, "words": "高的亲和力,从而抑制了VEGF-A与其受体 VEGFR-1和 VEGFR-2的结合。 VEGFA"}, {"probability": {"variance": 2e-06, "average": 0.999028, "min": 0.993342}, "location": {"width": 771, "top": 1136, "height": 34, "left": 210}, "words": "与其受体结合,可导致血管内皮细胞增殖和新生血管形成,以及增加血管渗漏"}, {"probability": {"variance": 0.021675, "average": 0.964286, "min": 0.174826}, "location": {"width": 889, "top": 1168, "height": 68, "left": 205}, "words": "所有这些被认为与新生血管性年龄相关性黄斑变性(AMD)的进展相关 PAARMACEUUA"}, {"probability": {"variance": 0.000405, "average": 0.993768, "min": 0.902553}, "location": {"width": 731, "top": 1231, "height": 35, "left": 253}, "words": "在新生血管性年龄相关性黄斑变性(AMD)患者中进行的三项随机、双盲"}, {"probability": {"variance": 0.004849, "average": 0.860947, "min": 0.763518}, "location": {"width": 179, "top": 1195, "height": 61, "left": 931}, "words": "士(中国"}, {"probability": {"variance": 0.012689, "average": 0.96074, "min": 0.511748}, "location": {"width": 904, "top": 1261, "height": 52, "left": 206}, "words": "假注射*或阳性对照的研究,评估了本品治疗的临床安全性与有效性。计323公司"}, {"probability": {"variance": 0.010428, "average": 0.957218, "min": 0.519601}, "location": {"width": 864, "top": 1293, "height": 49, "left": 206}, "words": "名病人(879名本品治疗组和44名对照组)入组至这三个临床期试验中在研"}, {"probability": {"variance": 0.000879, "average": 0.987867, "min": 0.846955}, "location": {"width": 787, "top": 1334, "height": 36, "left": 208}, "words": "究FVF2598g( MARINA)中,轻微典型性或隐匿型不含典型性CNV患者每月接"}, {"probability": {"variance": 0.000703, "average": 0.988798, "min": 0.833553}, "location": {"width": 787, "top": 1368, "height": 36, "left": 208}, "words": "受本品0.3mg或0.5mg或假注射的玻璃体内注射。总计716名患者入组此研究(假"}, {"probability": {"variance": 7.8e-05, "average": 0.994533, "min": 0.963991}, "location": {"width": 789, "top": 1401, "height": 38, "left": 207}, "words": "注射治疗组238名;本品0.3mg组238名;本品0.5mg组240名)。获得了24个月的研"}, {"probability": {"variance": 0, "average": 0.999489, "min": 0.999184}, "location": {"width": 69, "top": 1443, "height": 26, "left": 209}, "words": "究数据"}, {"probability": {"variance": 0.000218, "average": 0.992116, "min": 0.935075}, "location": {"width": 741, "top": 1498, "height": 31, "left": 253}, "words": "在研究FVF2587g( ANCHOR),典型性为主型CNV病变的患者接受:1)每"}], "language": 3}